A Trial to Evaluate Safety and Efficacy of Rivaroxaban (COVID-19)

Phase 2TerminatedNCT04504032

Gates Medical Research Institute497 enrolled

Overview

The purpose of this study is to assess safety and clinical efficacy of rivaroxaban in people with mild Coronavirus Disease 2019 who are at increased risk of disease progression.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

TRIPLE

Enrollment

497

Conditions

COVID-19

Interventions

RivaroxabanDRUG

Participants self-administered rivaroxaban, 10 milligrams (mg) (1 tablet) orally once daily for 21 days.

PlaceboDRUG

Participants self-administered rivaroxaban matching placebo orally once daily for 21 days.

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Participants must be at high-risk for Coronavirus disease 2019 (COVID-19) disease progression by fulfilling at least one of the following criteria at screening: * Presence of chronic pulmonary disease, chronic obstructive pulmonary disease (COPD), pulmonary hypertension * Diabetes mellitus (type 1 or type 2), requiring oral medication or insulin for treatment * Hypertension, requiring at least one oral medication for treatment * Immunocompromised status due to disease (e.g., those living with human immunodeficiency virus with a cluster of differentiation 4 \[CD4\] T-cell count of \<200 per cubic millimeter \[mm\^3\]) * Immunocompromised status due to medication (e.g., taking 20 milligram \[mg\] or more of prednisone equivalents a day, anti-inflammatory monoclonal antibody therapies, cancer therapies) * Any chronic disease that is associated with high risk for severe COVID in the opinion of the site investigator * Body mass index ≥35 Kilogram per square meter (kg/m\^2) (based on self-reported weight and height). * Documented Severe Acute Respiratory Syndrome Coronavirus 2 positive diagnostic test of ≤7 days at the time of screening * Symptomatic for COVID-19 for ≤72 hours at the time of screening (defined as having at least 2 of the following symptoms of COVID-19 that is of new onset or has worsened from baseline, and include fever, chills, myalgia, arthralgia, headache, fatigue, cough, sore throat, nasal congestion, anosmia, ageusia, nausea, vomiting, or diarrhea. If only two symptoms are present, they cannot both be anosmia and ageusia) * Capable of giving informed consent, which includes compliance with the requirements and restrictions listed in the inform consent form and in this protocol * Agree to participate in all remote, in-person or home visits as required in the protocol and provide updated contact information as necessary. * Female of childbearing potential must agree to practice adequate contraception during the study Exclusion Criteria: Participants are excluded from the study if any of the following criteria apply: * Currently hospitalized or under immediate consideration for hospitalization at screening and Day 1 * Have new onset shortness of breath or increased shortness of breath from pre-COVID-19 (for people with known COPD) at screening and Day 1 * Hypoxemia (oxygen saturation \<94% in ambient air or oxygen saturation below pre-COVID-19 level for people with known COPD) at Day 1 * Require supplemental oxygen (new requirement or increase in requirement from pre-COVID-19 condition) at screening and Day 1 * Have a history of (in the past 3 months) or current active pathological bleeding * Have a history of hemorrhagic stroke or intracranial hemorrhage * Have a recent severe head trauma within 30 days which includes concussion, skull fracture or hospitalization for head injury * Have known intracranial neoplasm, cerebral metastases, arteriovenous malformation or aneurysm * Have history of pregnancy-related hemorrhage * Have active gastroduodenal ulcer or other gastrointestinal bleeding diagnosed in the past 3 months * Currently are in a hemodynamically unstable state * Currently require thrombolysis or pulmonary embolectomy * Have history of severe hypersensitivity reaction to Xarelto® * Currently have a prosthetic heart valve * Have known diagnosis of triple positive antiphospholipid syndrome * Have known diagnosis of chronic kidney disease (stage IV or receiving dialysis) * Have a history of thrombocytopenia or known platelet count \<100,000 cells/mm\^3 * Have history of bronchiectasis and pulmonary cavitation * Have active cancer (e.g, receiving chemotherapy or treatment for complication of the active cancer) * Had epidural or neuraxial anesthesia or spinal puncture in the past 2 weeks and plan to undergo these procedures during the study * Had surgery in the past 4 weeks or plan to undergo surgery during the study * Currently is pregnant or plans to become pregnant * Currently is breastfeeding * Share household with an enrolled participant in this study * Co-enrollment in any clinical trial that includes prohibited procedures (spinal puncture or surgery) or that includes treatments within the same drug class as rivaroxaban or treatments for which co-administration with rivaroxaban are prohibited. Note that any co-enrollment other than this requires approval by the Sponsor. For any co-enrolled study, the total volume of blood samples collected across the studies should not exceed 275 milliliters (mL) in 4 weeks. * Currently using and plan to use the following medications during the study * Rivaroxaban or drugs in the same class * Dual anti-platelets therapy * Other anticoagulants * Combined Permeability glycoprotein (P-gp) and cytochrome P450 3A (CYP3A) inhibitors and inducers

Locations (20)

Woodland Research Northwest LLC - ERG - PPDS

Rogers, Arkansas, United States

Outcomes

Primary Outcomes

Number of Participants With Grade 3 and Grade 4 Adverse Events (AEs) Through Day 35

An AE is any untoward medical occurrence that occurs in a participant. An AE can be any unfavorable and unintended sign (including abnormal laboratory findings), symptom, or disease temporally associated with treatment, whether considered related to the product. AEs may include the onset of a new illness or undesirable medical condition or the exacerbation of pre-existing medical conditions. AE severity was graded as Grade 3 (Severe) and Grade 4 (Potentially Life-threatening) per the specific toxicity grading by the Division of Acquired Immunodeficiency Syndrome (DAIDS) AE Grading Table.

Time frame: Up to Day 35

Number of Participants With AEs Resulting in Study Intervention Discontinuation Through Day 35

Time frame: Up to Day 35

Number of Participants With Serious Adverse Events Through Day 35

A serious AE is any untoward medical occurrence or effect, that, at any dose: results in death; is life-threatening; requires hospitalization or prolongation of existing hospitalization; results in persistent or significant disability or incapacity; is an important medical event that may not be immediately life-threatening or result in death or hospitalization but may jeopardize the participant or may require intervention to prevent one of the other outcomes.

Time frame: Up to Day 35

Number of Participants Who Progressed to Moderate or Severe Disease or Higher Based on the Gates MRI Ordinal Scale Through Day 28

Participants who progressed to a moderate or severe disease category or higher (Bill \& Melinda Gates Medical Research Institute \[Gates MRI\] ordinal scale ≥3) are reported. Gates MRI scale scores are assessed on a 7-point scale: 1=Asymptomatic/symptoms similar to pre-COVID-19 status; 2=Mild; 3=Moderate or severe; 4=Critically ill; 5=Critically ill with invasive mechanical ventilation or extrapulmonary complication; 6=Critically ill with Extra-Corporeal Membrane Oxygenation (ECMO); 7=Death.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

Secondary Outcomes

Median Time to Disease Resolution Based on Symptoms Resolution Through Day 28

Time to disease resolution is defined as the time from the first dose to the date of symptoms resolution (new-onset Coronavirus Disease 2019 \[COVID-19\] symptoms resolved, and pre-existing symptoms returned to Baseline) through Day 28. Baseline refers to health status prior to contracting new-onset COVID-19 symptoms. The 95% confidence interval (CI) for median and quartiles of time to disease resolution were calculated using the Kaplan Meier estimates.

Time frame: Up to Day 28

Median Time to Disease Resolution Based on Viral Clearance and Symptoms Resolution Through Day 28

Time to disease resolution is defined as the time from the first dose to the date of both viral clearance (two consecutive negative diagnostic tests) and symptoms resolution (new-onset COVID-19 symptoms resolved, and pre-existing symptoms returned to Baseline) through Day 28. Baseline refers to health status prior to contracting new-onset COVID-19 symptoms. The 95% CI for median and quartiles of time to disease resolution were calculated using the Kaplan Meier estimates.

Time frame: Up to Day 28

Number of Participants Who Progressed to Moderate or Severe Disease or Higher Based on the Gates MRI Ordinal Scale at Day 8, 14, and 21

Participants who progressed to a moderate or severe disease category or higher (Gates MRI ordinal scale ≥3) are reported. Gates MRI ordinal scale scores are assessed on a 7-point scale: 1=Asymptomatic/symptoms similar to pre-COVID-19 status; 2=Mild; 3=Moderate or severe; 4=Critically ill; 5=Critically ill with invasive mechanical ventilation or extrapulmonary complication; 6=Critically ill with ECMO; 7=Death.

Time frame: Days 8, 14, and 21

Number of Participants Who Achieved Disease Resolution Based on Symptoms Resolution at Days 8, 14, 21, and 28

Symptoms resolution is defined as new-onset COVID-19 symptoms resolved, and pre-existing symptoms returned to Baseline. Baseline refers to health status prior to contracting new-onset COVID-19 symptoms.